

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

PE Donkey anti-rabbit IgG (min. x-reactivity)

RRID:AB_2563484

Type: Antibody

Proper Citation

BioLegend Cat# 406421, RRID:AB_2563484

Antibody Information

URL: http://antibodyregistry.org/AB_2563484

Proper Citation: BioLegend Cat# 406421, RRID:AB_2563484

Target Antigen: Rabbit IgG

Host Organism: Donkey

Clonality: polyclonal

Comments: Applications: FC

Antibody Name: PE Donkey anti-rabbit IgG (min. x-reactivity)

Description: This polyclonal targets Rabbit IgG

Target Organism: rabbit

Clone ID: Clone Poly4064

Antibody ID: AB_2563484

Vendor: BioLegend

Catalog Number: 406421

Record Creation Time: 20231110T035215+0000

Record Last Update: 20260829T161237+0000

Ratings and Alerts

No rating or validation information has been found for PE Donkey anti-rabbit IgG (min. x-reactivity).

No alerts have been found for PE Donkey anti-rabbit IgG (min. x-reactivity).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Weber JL, et al. (2026) De novo pyrimidine synthesis controls germinal center B cell and plasma cell fates and systemic autoimmunity. *Cell reports*, 45(7), 117587.

Stevens J, et al. (2025) Microbiota-derived inosine programs protective CD8+ T cell responses against influenza in newborns. *Cell*, 188(16), 4239.

Poddar S, et al. (2025) ArfGAP2 promotes STING proton channel activity, cytokine transit, and autoinflammation. *Cell*, 188(6), 1605.

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. *STAR protocols*, 6(2), 103742.

Kim AR, et al. (2025) Co-blockade of TGF β and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGF β RI Expression. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3306.

Zhang L, et al. (2025) Periplakin Attenuates Liver Fibrosis via Reprogramming CD44^{Low} Cells into CD44^{High} Liver Progenitor Cells. *Cellular and molecular gastroenterology and hepatology*, 19(7), 101498.

Conter L, et al. (2025) BLIMP1 controls GC B cell expansion and exit through regulating cell cycle progression and key transcription factors BCL6 and IRF4. *Cell reports*, 44(7), 115977.

Zhou W, et al. (2025) ILC3s sense gut microbiota through STING to initiate immune tolerance. *Immunity*, 58(7), 1762.

Du XY, et al. (2025) Attenuating α -synuclein pathology in mice with in situ engineered astrocytes. *Translational neurodegeneration*, 14(1), 58.

Fang Y, et al. (2025) Protocol to generate allojection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. *STAR protocols*, 6(2), 103810.

Grun CN, et al. (2024) Bacterial cell surface characterization by phage display coupled to high-throughput sequencing. *Nature communications*, 15(1), 7502.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. *Cancer cell*.

Wang Y, et al. (2024) Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. *Cell reports. Medicine*, 5(1), 101374.

Chun D, et al. (2024) Flt3L enhances clonal diversification and selective expansion of intratumoral CD8+ T cells while differentiating into effector-like cells. *Cell reports*, 43(12), 115023.

Marx AF, et al. (2023) The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1+ CD8+ T cells in chronic viral infection. *Immunity*, 56(4), 813.

Linde IL, et al. (2023) Neutrophil-activating therapy for the treatment of cancer. *Cancer cell*, 41(2), 356.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. *Cell*, 186(16), 3333.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. *iScience*, 26(10), 107952.

Campar A, et al. (2023) Muscle glycome in idiopathic inflammatory myopathies: Impact in IL-6 production and disease prognosis. *iScience*, 26(7), 107172.

Jarosch S, et al. (2023) Multimodal immune cell phenotyping in GI biopsies reveals microbiome-related T cell modulations in human GvHD. *Cell reports. Medicine*, 4(7), 101125.